Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Kinnate Biopharma

KNSA

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Kinnate Biopharma. A complete text table follows the diagram.

Kinnate Biopharma Pipeline Revenue Flow

A specialty-therapeutics platform remains the operating story, with no current collaboration revenue.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001104659-26-050359
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

The filing reports $214.266M of total revenue and no collaboration revenue; this view centers the company-specific therapeutics platform.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Kinnate Biopharma revenue	1	$214M	$214.266M reported quarterly revenue
Therapeutics and development platform	2	$214M	Reported total revenue

Financial flows · Millions of USD
From	To	Value
Kinnate Biopharma revenue	Therapeutics and development platform	$214M